Burmester G - Search Results

1

A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.

Cobb P, Niederwieser D, Cohen S, Hamm C, Burmester G, Seo N, Lehto SG, Hanes V. Cobb P, et al. Among authors: burmester g. Immunotherapy. 2022 Jun;14(9):727-740. doi: 10.2217/imt-2022-0024. Epub 2022 May 11. Immunotherapy. 2022. PMID: 35543293 Free article. Review.

2

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group. Cohen SB, et al. Arthritis Rheum. 2006 Sep;54(9):2793-806. doi: 10.1002/art.22025. Arthritis Rheum. 2006. PMID: 16947627 Free article. Clinical Trial.

3

A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.

Burmester G, Chien D, Chow V, Gessner M, Pan J, Cohen S. Burmester G, et al. Clin Pharmacol Drug Dev. 2020 Nov;9(8):1003-1014. doi: 10.1002/cpdd.845. Epub 2020 Jul 5. Clin Pharmacol Drug Dev. 2020. PMID: 32627420 Clinical Trial.

4

Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.

Burmester G, Drescher E, Hrycaj P, Chien D, Pan Z, Cohen S. Burmester G, et al. Clin Rheumatol. 2020 Nov;39(11):3341-3352. doi: 10.1007/s10067-020-05305-y. Epub 2020 Sep 2. Clin Rheumatol. 2020. PMID: 32876780 Free PMC article. Clinical Trial.

5

Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.

Burmester G, Drescher E, Hrycaj P, Chien D, Pan Z, Cohen S. Burmester G, et al. Clin Rheumatol. 2020 Nov;39(11):3527. doi: 10.1007/s10067-020-05410-y. Clin Rheumatol. 2020. PMID: 32965602 Free PMC article.

6

Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.

Conaghan PG, Mysler E, Tanaka Y, Da Silva-Tillmann B, Shaw T, Liu J, Ferguson R, Enejosa JV, Cohen S, Nash P, Rigby W, Burmester G. Conaghan PG, et al. Among authors: burmester g. Drug Saf. 2021 May;44(5):515-530. doi: 10.1007/s40264-020-01036-w. Epub 2021 Feb 2. Drug Saf. 2021. PMID: 33527177 Free PMC article. Review.

7

Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.

Conaghan P, Cohen S, Burmester G, Mysler E, Nash P, Tanaka Y, Rigby W, Patel J, Shaw T, Betts KA, Patel P, Liu J, Sun R, Fleischmann R. Conaghan P, et al. Among authors: burmester g. Rheumatol Ther. 2022 Feb;9(1):191-206. doi: 10.1007/s40744-021-00399-5. Epub 2021 Nov 23. Rheumatol Ther. 2022. PMID: 34816388 Free PMC article.

8

Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis.

Dörner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G; International Roundtable on B cells as Therapeutic Target for Intervention. Dörner T, et al. Among authors: burmester g. Autoimmun Rev. 2009 Dec;9(2):82-9. doi: 10.1016/j.autrev.2009.08.007. Epub 2009 Aug 27. Autoimmun Rev. 2009. PMID: 19716441 Review.

9

Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab.

Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann KG, Maza S, Keitzer R, Burmester GR, Buttgereit F, Radbruch A, Hiepe F. Hoyer BF, et al. Ann Rheum Dis. 2012 Jan;71(1):75-9. doi: 10.1136/ard.2011.153007. Epub 2011 Sep 27. Ann Rheum Dis. 2012. PMID: 21953334

10

Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).

Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, Kötter I, Henes JC, Bergner R, Rubbert-Roth A, Specker C, Schulze-Koops H, Müller-Ladner U, Fleck M, Burmester GR, Hiepe F, Heitmann S, Aringer M, Fischer-Betz R, Dörner T, Tony HP. Roll P, et al. J Rheumatol. 2012 Nov;39(11):2153-6. doi: 10.3899/jrheum.120482. Epub 2012 Sep 15. J Rheumatol. 2012. PMID: 22984269

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,004 results

Search Page